IBDEI1HE ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,23685,1,4,0)
 ;;=4^E05.91
 ;;^UTILITY(U,$J,358.3,23685,2)
 ;;=^5002493
 ;;^UTILITY(U,$J,358.3,23686,0)
 ;;=E27.40^^105^1185^1
 ;;^UTILITY(U,$J,358.3,23686,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23686,1,3,0)
 ;;=3^Adrenal Insufficiency,Unspec
 ;;^UTILITY(U,$J,358.3,23686,1,4,0)
 ;;=4^E27.40
 ;;^UTILITY(U,$J,358.3,23686,2)
 ;;=^5002742
 ;;^UTILITY(U,$J,358.3,23687,0)
 ;;=Z79.84^^105^1185^42
 ;;^UTILITY(U,$J,358.3,23687,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23687,1,3,0)
 ;;=3^Long Term (Current) Use of Oral Hypoglycemic Drugs
 ;;^UTILITY(U,$J,358.3,23687,1,4,0)
 ;;=4^Z79.84
 ;;^UTILITY(U,$J,358.3,23687,2)
 ;;=^5140432
 ;;^UTILITY(U,$J,358.3,23688,0)
 ;;=Z79.4^^105^1185^41
 ;;^UTILITY(U,$J,358.3,23688,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23688,1,3,0)
 ;;=3^Long Term (Current) Use of Insulin
 ;;^UTILITY(U,$J,358.3,23688,1,4,0)
 ;;=4^Z79.4
 ;;^UTILITY(U,$J,358.3,23688,2)
 ;;=^5063334
 ;;^UTILITY(U,$J,358.3,23689,0)
 ;;=E11.9^^105^1185^39
 ;;^UTILITY(U,$J,358.3,23689,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23689,1,3,0)
 ;;=3^DM 2 w/o Complications
 ;;^UTILITY(U,$J,358.3,23689,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,23689,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,23690,0)
 ;;=E11.40^^105^1185^21
 ;;^UTILITY(U,$J,358.3,23690,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23690,1,3,0)
 ;;=3^DM 2 w/ Neuropathy
 ;;^UTILITY(U,$J,358.3,23690,1,4,0)
 ;;=4^E11.40
 ;;^UTILITY(U,$J,358.3,23690,2)
 ;;=^5002644
 ;;^UTILITY(U,$J,358.3,23691,0)
 ;;=E11.00^^105^1185^5
 ;;^UTILITY(U,$J,358.3,23691,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23691,1,3,0)
 ;;=3^DM 2 w/ Hypersmolarity w/o NKHHC
 ;;^UTILITY(U,$J,358.3,23691,1,4,0)
 ;;=4^E11.00
 ;;^UTILITY(U,$J,358.3,23691,2)
 ;;=^5002627
 ;;^UTILITY(U,$J,358.3,23692,0)
 ;;=E11.01^^105^1185^4
 ;;^UTILITY(U,$J,358.3,23692,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23692,1,3,0)
 ;;=3^DM 2 w/ Hyperosmolarity w/ Coma
 ;;^UTILITY(U,$J,358.3,23692,1,4,0)
 ;;=4^E11.01
 ;;^UTILITY(U,$J,358.3,23692,2)
 ;;=^5002628
 ;;^UTILITY(U,$J,358.3,23693,0)
 ;;=E11.21^^105^1185^20
 ;;^UTILITY(U,$J,358.3,23693,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23693,1,3,0)
 ;;=3^DM 2 w/ Nephropathy
 ;;^UTILITY(U,$J,358.3,23693,1,4,0)
 ;;=4^E11.21
 ;;^UTILITY(U,$J,358.3,23693,2)
 ;;=^5002629
 ;;^UTILITY(U,$J,358.3,23694,0)
 ;;=E11.22^^105^1185^2
 ;;^UTILITY(U,$J,358.3,23694,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23694,1,3,0)
 ;;=3^DM 2 w/ Chr Kidney Disease
 ;;^UTILITY(U,$J,358.3,23694,1,4,0)
 ;;=4^E11.22
 ;;^UTILITY(U,$J,358.3,23694,2)
 ;;=^5002630
 ;;^UTILITY(U,$J,358.3,23695,0)
 ;;=E11.51^^105^1185^33
 ;;^UTILITY(U,$J,358.3,23695,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23695,1,3,0)
 ;;=3^DM 2 w/ Peripheral Angiopathy w/o Gangrene
 ;;^UTILITY(U,$J,358.3,23695,1,4,0)
 ;;=4^E11.51
 ;;^UTILITY(U,$J,358.3,23695,2)
 ;;=^5002650
 ;;^UTILITY(U,$J,358.3,23696,0)
 ;;=E11.52^^105^1185^32
 ;;^UTILITY(U,$J,358.3,23696,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23696,1,3,0)
 ;;=3^DM 2 w/ Peripheral Angiopathy w/ Gangrene
 ;;^UTILITY(U,$J,358.3,23696,1,4,0)
 ;;=4^E11.52
 ;;^UTILITY(U,$J,358.3,23696,2)
 ;;=^5002651
 ;;^UTILITY(U,$J,358.3,23697,0)
 ;;=E11.641^^105^1185^6
 ;;^UTILITY(U,$J,358.3,23697,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23697,1,3,0)
 ;;=3^DM 2 w/ Hypoglycemia w/ Coma
 ;;^UTILITY(U,$J,358.3,23697,1,4,0)
 ;;=4^E11.641
 ;;^UTILITY(U,$J,358.3,23697,2)
 ;;=^5002661
